Consensus LifeMD, Inc.

Stocks

LFMD

US53216B1044

Advanced Medical Equipment & Technology

Market Closed - Nasdaq 16:00:00 2026-09-03 EDT			5-day change	1st Jan Change
3.050 ^USD	-0.65%		-6.44%	-10.56%

08-06	B. Riley Adjusts Price Target on LifeMD to $8 From $10, Maintains Buy Rating	MT
08-05	LifeMD, Inc., Q2 2026 Earnings Call, Aug 05, 2026

Evolution of the Average Target: LifeMD, Inc.

Evolution of the Target Price: LifeMD, Inc.

Changes in Analyst Recommendations: LifeMD, Inc.

07dc4cf0b186eb532fe33effd.WJZHfZEweDnuoQeQ4udnNFC3eESuEz8J3_7AApkRc0o.EP49SPVWSVyGkUjG0JQ4WSH5EyKaY3tomJefZeNVQD8w1zYPpXgNdIHPVg~22a29449e2e62654ffa95501adc83511

Analysts' recommendations: LifeMD, Inc.

08-06	B. Riley Adjusts Price Target on LifeMD to $8 From $10, Maintains Buy Rating	MT
03-16	Mizuho Upgrades LifeMD to Outperform From Neutral, Adjusts Price Target to $8 From $6	MT
01-16	Novo's Wegovy pill makes encouraging start in weight-loss race vs Lilly	RE
01-05	Sector Update: Health Care Stocks Decline Late Afternoon	MT
11-18	B. Riley Adjusts Price Target on LifeMD to $10 From $12, Maintains Buy Rating	MT
25-01-08	KeyBanc Cuts Price Target on LifeMD to $7.50 From $10, Keeps Overweight Rating	MT
24-12-04	Mizuho Initiates LifeMD at Neutral With $7 Price Target	MT
24-11-08	B. Riley Adjusts Price Target on LifeMD to $12 From $11, Maintains Buy Rating	MT
24-08-08	B. Riley Trims Price Target on LifeMD to $11 From $12, Maintains Buy Rating	MT
24-07-11	KeyBanc Adjusts Price Target on LifeMD to $10 From $12, Maintains Overweight Rating	MT
24-06-05	KeyBanc Initiates LifeMD at Overweight With $12 Price Target, Cites 'Strong Top & Bottom-Line Growth'	MT
24-05-09	Cantor Fitzgerald Adjusts LifeMD's Price Target to $15 From $13, Keeps Overweight Rating	MT
24-04-23	BTIG Adjusts LifeMD's Price Target to $14 From $13, Keeps Buy Rating	MT
24-03-12	Craig-Hallum Adjusts LifeMD's Price Target to $15 From $10, Maintains Buy Rating	MT
24-03-12	Cantor Fitzgerald Adjusts Price Target on LifeMD to $11 From $9, Maintains Overweight Rating	MT
24-03-12	B. Riley Securities Lifts LifeMD's PT to $12 From $11 After 'Strong' Q4 2023 Results, Maintains Buy Rating	MT
24-01-11	HC Wainwright Adjusts LifeMD Price Target to $12 From $10, Maintains Buy Rating	MT
23-11-14	Cantor Fitzgerald Adjusts LifeMD's Price Target to $9 From $8, Maintains Overweight Rating	MT
23-11-09	HC Wainwright Adjusts Price Target on LifeMD to $10 From $9, Maintains Buy Rating	MT
23-11-09	B. Riley Raises LifeMD's Price Target to $11 From $7 After Q3 Topline Beat, Maintains Buy Rating	MT
23-10-02	Cantor Fitzerald Adjusts LifeMD Price Target to $8 From $7, Maintains Overweight Rating	MT
23-07-21	Cantor Fitzgerald Starts LifeMD at Overweight With $7 Price Target	MT
23-07-10	B. Riley Raises LifeMD's PT to $7 From $3.50 on Increased Conviction for Durable Growth, Enhanced EBITDA; Keeps Buy Rating	MT
23-07-03	HC Wainwright Initiates LifeMD With Buy Rating, $9 Price Target	MT
23-03-23	BTIG Research Adjusts LifeMD Price Target to $7 From $8, Maintains Buy Rating	MT

More recommendations

Medical Software & Technology Services

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
LIFEMD, INC.			+164.66%
VEEVA SYSTEMS INC.			+5.15%
PRO MEDICUS LIMITED			+17.43%
SECTRA AB			+18.72%
HEARTFLOW, INC.			-13%
GENERATE BIOMEDICINES, INC.			+65.85%
OMNICELL, INC.			+66.69%
XUNFEI HEALTHCARE TECHNOLOGY CO., LTD.	-		+51.02%
ARBUTUS BIOPHARMA CORPORATION	-	-	+7.84%
Average			+42.71%
Weighted average by Cap.			+11.31%